Scale-down modeling accelerates the development of downstream biopharma manufacturing processes. Biopharmaceutical manufacturing involves a series of complex unit operations linked together to provide ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

With multiple, complex chromatographic purification, buffer exchange, and viral inactivation steps, downstream processing of monoclonal antibodies (mAbs) remains the major bottleneck in ...

Drug development and manufacturing have undergone a seismic shift in the last two decades, 1 from blockbuster small molecules to highly personalized biologics 2 and cell and gene therapies. Because ...

Gene therapy has emerged as a cutting-edge modality with transformative potential for treating a broad range of genetic disorders. Despite significant advancements, the purification and separation of ...

Biopharmaceutical downstream processing requires precise control of multiple unit operations—from chromatography and filtration to viral inactivation—to ensure product quality and therapeutic efficacy ...

Purifying novel therapeutics remains a major challenge as increasingly complex molecules move towards the clinic. With Lonza, you can ensure optimal product quality and bring your molecules to the ...

Your Roadmap for mRNA Process Development & Manufacturing with Optimized Purification, Process Analytics & Enhanced Formulation to Improve Cost-Effectiveness & Scalability into the Clinic & Beyond The ...

Isomerase, a leader in contract fermentation process development, is proud to announce the integration of its process innovation capabilities into its end-to-end platform for protein discovery and ...